GENZYME ACQUISITION OF BIOSURFACE TECHNOLOGY
This article was originally published in The Gray Sheet
Executive SummaryGENZYME ACQUISITION OF BIOSURFACE TECHNOLOGY will create a free-standing tissue repair business with a $20 mil. research and development budget in its first year. The combination of the two firms' tissue repair portfolios will give Genzyme "the most comprehensive technology base" in the field, the company says in a July 26 press release announcing the deal.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.